FULC - Fulcrum Therapeutics, Inc.
| Previous Close | 11.49 |
| Open | 11.21 |
| Bid | 0.00 x 800 |
| Ask | 0.00 x 800 |
| Day's Range | 10.72 - 11.56 |
| 52 Week Range | 8.19 - 15.94 |
| Volume | 84,452 |
| Avg. Volume | 127,212 |
| Market Cap | 321.456M |
| Beta (3Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -7.21 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- GlobeNewswire
Fulcrum Therapeutics Announces Initiation of ReDUX4, a Phase 2b Clinical Trial of Losmapimod for FSHD
CAMBRIDGE, Mass., Aug. 19, 2019 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced it has initiated ReDUX4, a Phase 2b clinical trial of losmapimod in facioscapulohumeral muscular dystrophy (FSHD). “We are excited to evaluate losmapimod’s efficacy and safety in FSHD, a disease for which there are currently no approved treatments,” said Robert J. Gould, Ph.D., Fulcrum’s president and chief executive officer.
- GlobeNewswire
Fulcrum Therapeutics to Present at the SVB Leerink Spotlight Series: Rare & Genetic Diseases Conference
CAMBRIDGE, Mass., Aug. 01, 2019 -- Fulcrum Therapeutics, Inc. (Nasdaq:FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with.
- GlobeNewswire
Fulcrum Therapeutics Announces Pricing of Initial Public Offering
CAMBRIDGE, Mass., July 17, 2019 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (the “Company”) (Nasdaq:FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined diseases in areas of high unmet medical need, with an initial focus on rare diseases, today announced the pricing of its initial public offering of 4,500,000 shares of common stock at a public offering price of $16.00 per share, for gross proceeds of $72.0 million, before underwriting discounts and commissions and offering expenses payable by the Company. In addition, the Company has granted the underwriters a 30-day option to purchase up to 675,000 additional shares of common stock at the initial public offering price, less underwriting discounts and commissions.
- Benzinga
IPO Outlook For The Week: Biotechs, Financial Advisers, Medical Services And The Twitch Of China
For a more comprehensive IPO calendar, check out the offering in Benzinga Cloud . The IPO dates below are expected but not confirmed. Douyu International Holdings Ltd (DOYU) will issue nearly 67.4 million ...
- Benzinga
Fulcrum Therapeutics IPO: What You Need To Know
Cambridge, Massachusetts-based Fulcrum Therapeutics, Inc. is planning a 4.5-million-share IPO at an estimated price range of $16-$18, according to the S-1/A filed with the SEC July 8. The company uses its product engine to identify targets that can be drugged by small molecules, regardless of the particular underlying mechanism of gene misexpression. The company said it is planning to initiate a Phase 2b clinical trial of losmapimod, its product candidate for facioscapulohumeral muscular dystrophy, in mid-2019.
